Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1993-11-12
1996-07-09
Criares, T. J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514560, 514561, 514562, 514564, 514567, 514400, 514423, 514419, A61K 31195, A61K 31385, A61K 3140
Patent
active
055345450
ABSTRACT:
An anti-hypotensive formulation comprising an essentially arginine-free or low arginine (less than about 0.1%, most preferably, about 0.01%) containing mixture of amino acids is provided. The invention in particular embodiments of the anti-hypotensive formulation includes ornithine, citrulline or both. A method for prophylaxis and treatment of systemic hypotension in an animal is provided. Most particularly, a method for treating hypotension caused by nitric oxide synthesis through administering a low or essentially arginine-free parenteral formulation to an animal, so as to reduce or eliminate nitric oxide synthesis is described. A method for treating an animal in septic shock is also disclosed, comprising administering to the animal an anti-hypotensive formulation comprising a mixture of amino acids, which is essentially arginine free.
REFERENCES:
patent: 3950529 (1976-04-01), Fischer et al.
patent: 4734420 (1988-03-01), Ryan et al.
patent: 4859452 (1989-08-01), Ajani et al.
patent: 4988724 (1991-01-01), Ajani et al.
patent: 5006559 (1991-04-01), Askanazi et al.
patent: 5028627 (1991-07-01), Kilbourn et al.
patent: 5036052 (1991-07-01), Ozeki et al.
patent: 5059712 (1991-10-01), Griffith
patent: 5132453 (1992-07-01), Griffith
patent: 5158883 (1992-10-01), Griffith
patent: 5162373 (1992-11-01), Ajani et al.
patent: 5189025 (1993-02-01), Ajani et al.
patent: 5216025 (1993-06-01), Gross et al.
patent: 5286739 (1994-02-01), Kilbourn et al.
Remington's Pharmaceutical Sciences, Fifteenth Edition, Mack Publishing Company, (1976).
Kilbourn et al., (1990), Journal Nat'l Cancer Inist., 82(9):772-776.
Kilbourn et al., (May 1990), Proc. Natl. Acad. Sci. USA, 87:3629-32.
Sakuma et al., (1988), Proc. Natl. Acad. Sci. USA, 85:8664-67.
Stuehr et al., (1989), J. Exp. Med., 169:1011-20.
Hibbs et al., (1988), Biochem Biophys. Res. Comm. 157(1):87-94.
Stuehr et al., (1987), J. Immunology, 139:518-525.
Palmer et al., (1987), Nature, 327:524-526.
Natanson et al. (1989), J. Exp. Med., 169:823-832.
Starnes et al. (1988), J. Clin. Invest., (82(4):1321-25.
Nathan et al., (1991) Journal Natl Cancer Inst. (USA), 82(9):726-28.
Schmidt et al., (1988), European J. of Pharmacology, 154:213-216.
Moncada et al., "Nitric Oxide: Physiology, Pathophysiology, and Pharmacology," Pharmacological Reviews, 43(2):109-142, 1991, published in USA.
Moncada et al., "The L-Arginine: Nitric Oxide Pathway," Journal of Cardiovascular Pharmacology, 17(Suppl. 3):S1-S9, 1991, published in USA.
Parratt, J. R., and Stoclet, Jean-Claude, "Possible Role of Nitric Oxide in Refractory Hypotension Associated with Sepsis and Endotoxaemia and with Multiple Organ Failure," Applied Cardiopulmonary Pathophysiology, 4:143-149, 1991, published in USA.
Johnston, Jeff, "Molecular Science Sets Its Sights On Septic Shock," The Journal of NIH Research, 3:61-65, 1991, published in USA.
Moncada, S., and Higgs, E. A., "Endogenous Nitric Oxide: Physiology, Pathology nd Clinical Relevance," European Journal of Clinical Investigation, 21:361-374, 1991, published in Europe.
Martin et al., "Selective Blockade of Endothelium-Dependent and Glyceryl Trinitrate-Induced Relaxation by Hemoglobin and by Methylene Blue in the Rabbit Aorta," The Journal of Pharmacology and Experimental Therapeutics, 232(3):708-716, 1985, published in USA.
Buga et al., "Endothelium-Derived Nitric Oxide Relaxes Nonvascular Smooth Muscle," European Journal of Pharmacology, 161:61-72, 1989, published in Europe.
Stuehr et al., "Synthesis of Nitrogen Oxides from L-Arginine by Macrophage Cytosol: Requirement for Inducible and Constitutive Components," Biochemical and BiophysicalResearch Communications, 161(2):420426, 1989, published in USA.
Aisaka et al., "N.sup.G Methylarginine, An Inhibitor ofEndothelium-Derived Nitric Oxide Synthesis, Is A Potent Pressor Agent in The Guinea Pig: Does Nitric Oxide Regulate Blood Pressure In Vivo?" Biochemical and Biophysical Research Communications, 160(2):881-886, 1989, published in USA.
Torti et al., "A Macrophage Factor Inhibits Adipocyte Gene Expression: An in Vitro Model of Cachexia," Science, 229:867-871, 1985, published in USA.
Kilbourn et al., "Activiated Macrophages Secrets a Soluble Factor That Inhibits Mitochondrial Respiration ofTumor Cells, " The Journal of Immunology, 133(5):2577-2588, 1984, published in USA.
Vallance et al., "Effects of Endothelium-Derived Nitric Oxide on Peripheral Arteriolar Tone in Man," The Lancet, Ltd., 997-999, Oct., 1989, published in Europe.
Palmer et al., "Vascular Endothelial Cells Synthesize Nitric Oxide from L-Arginine," Nature, 333:664-666, 1988, published in Europe.
Old, Loyd J., "Tumor Necrosis Factor (TNF)," Science, 23:630-632, 1985, published in USA.
Yoshida and Kasama, "Biotransformation of Nitric Oxide," Environmental Health Perspectives, 78:201-206, 1987, published in USA.
Reif and Simmons, "Nitric Oxide Mediates Iron Release form Ferritin," Archives of Biochemistry and Biophysics, 238(2):537-541, 1990, published in USA.
Kruszyna et al., "Nitrite Conversion to Nitric Oxide in Red Cells and Its Stabilization as a Nitrosylated Valency Hybrid of Hemoglobin, " The Journal of Pharmacology and Experimental Therapeutics, 241(1):307-313, 1987, published in USA.
Kosaka et al., "The Interaction Between Nitrogen Oxides and Hemoglobin and Endothelium-Derived Relaxing Factor," Free Radical Biology and Medicine, 7:653-658, 1989, published in USA.
Chevion et al., "Iron-Nitrosyl Bond Configuration in Nitrosyl-Hemoproteins: A Comparative EPR Study of Hemoglobin A and Hemoglobin Kansas," Israel Journal of Chemistry, 15:311-317, 1976, publisheed in Israel.
Collier and Vallance, "Second Messenger Role for NO Widens to Nervous and Immune Systems," Trends in Pharmacological Sciences Including Toxicological Sciences, Elseview Science Publishers, Ltd., front page and pp. 428-431, 1989, published in United Kingdom.
Ignarro et al., "Endothelium-Derived Relaxing Factor Produced and Released from Artery and Vein is Nitric Oxide," Proc. Natl. Acad. Sci. USA, 84:9265-9269, 1987, published in USA.
Murray et al., "Stabilization and Partial Characterization of Endothelium-Derived Relaxing Factor from Cultured Bovine Aortic Endothelial Cells," Biochemical and Biopiophysical Research Communications, 141(2):689-696, 1986, published in USA.
Gross et al., "Cytokine-Activiated Endothelial Cells Express An Isotype Of Nitric Oxide Synthase Which is Tetrahydrobiopterin-Dependent Calmodulin-Independent Andinhibited By Arginine Analogs With A Rank-Ordre Ofpotency Characteristic Of Activiated Macrophages," Biochem. and Biophys. Research Comm., 178(3):823-829, 1991.
Gross et al., "Macrophage And Endothelial Cell Nitric Oxide Synthesis: Cell-Type Selective Inhibition By N.sup.G -Nitroarginine and N.sup.G -Methylarginine," Biochem. and Biophys. Research Comm., 170(1):96-103, 1990.
Kilbourn et al., "Reversal Of Endotoxin-Mediated Shock By N.sup.G -Methy-L-Arginine, An Inhibitoro F Nitric Oxide Synthesis," Biochem. and Biophys. Research Comm., 172(3):1132-1138, 1990.
PCT search report dated Jan. 22, 1991.
Kilbourn and Griffith, "Overproduction of Nitric Oxide in Cytokine-Mediated and Spetic Shock," Jr. of the Nat'l. Cancer Inst., 84(11):827-831, 1992.
Griffith Owen W.
Gross Steven S.
Kilbourn Robert G.
Board of Regents , The University of Texas System
Cornell Research Foundation Inc.
Criares T. J.
LandOfFree
Parenteral amino acid formulations for the inhibition of systemi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Parenteral amino acid formulations for the inhibition of systemi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Parenteral amino acid formulations for the inhibition of systemi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1867584